Agoracom Blog

VIDEO – Novamind $ $NVMDF Discusses Partnership with Merck for New Treatment-Resistant Depression Trial $ $MMED $ $ $CMPS $

Posted by AGORACOM-JC at 5:22 PM on Monday, March 22nd, 2021

Last week Novamind (NM: CSE:) (NVMDF: OTC) (HN2: FSE) announced that its wholly-owned subsidiary, Cedar Clinical Research has been selected as a key research site for a clinical trial focused on treatment-resistant depression by Merck & Co., a world-leading pharmaceutical company.

The phase II study will assess the efficacy and safety of a new Merck drug for treatment-resistant depression (TRD), a mental health condition that affects approximately 30% of people who suffer from major depressive disorder.  

Yaron Conforti, CEO and Director of Novamind said: “Under Dr. Robison’s leadership, Cedar Clinical Research has proven itself as a best-in-class research site for emerging mental health therapeutics. We’re excited to work with Merck, a world-class pharmaceutical company, to advance research for innovative mental health treatments.” 

Sit back, relax and watch this powerful interview with Yaron Conforti, CEO and Director of Novamind. 

Tags: , , , , ,

Comments are closed.